Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Normandt1965on Jun 08, 2022 4:17pm
164 Views
Post# 34741603

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliffCome on, you put the focus on the fact that oncy lost more than 100 patents in the last quarter. You even don't know which ones are lost. This is the best way for people to misslead shareholders. You asked why don't extend the actual patents expired in 2028, suggesting that the trials were possibly not finished.....another trick well known for sowing doubt. Finally you changed your approach....I'm not surprised. It's not because I don"t trust the oncy web site, that I took the numbers from wikipedia, it's because I didn't find them the first time and when I finally found something the update date, month and year were not indicated, but on a few other site the date was indicated.....thats all.....dont try to paint me in the corner as you do usually.
<< Previous
Bullboard Posts
Next >>